GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.

Forge Biologics has entered an AAV development and manufacturing agreement to help advance Fractyl Health’s Rejuva platform.

Ecolab Life Sciences has opened its new US Bioprocessing Applications Laboratory in King of Prussia, Pennsylvania.